|
US5538983A
(en)
|
1990-05-16 |
1996-07-23 |
The Rockefeller University |
Method of treating amyloidosis by modulation of calcium
|
|
CZ281628B6
(cs)
|
1991-07-29 |
1996-11-13 |
Warner-Lambert Company |
Deriváty chinazolinu a farmaceutické přípravky na jejich bázi
|
|
IT1255179B
(it)
|
1992-06-26 |
1995-10-20 |
Enzo Cereda |
Azaciclo e azabiciclo alchiliden idrossilamine
|
|
US5744476A
(en)
|
1994-06-27 |
1998-04-28 |
Interneuron Pharmaceuticals, Inc. |
Dopamine D1 agonists for the treatment of dementia
|
|
JP2992677B2
(ja)
|
1995-06-05 |
1999-12-20 |
武田薬品工業株式会社 |
骨形成促進医薬組成物
|
|
WO1998030243A1
(en)
|
1997-01-08 |
1998-07-16 |
Warner-Lambert Company |
Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
|
|
CA2317942A1
(en)
*
|
1998-01-16 |
1999-07-22 |
Purdue Research Foundation |
Alkenyldiarylmethane non-nucleoside hiv-1 reverse transcriptase inhibitors
|
|
IL137517A0
(en)
|
1998-01-27 |
2001-07-24 |
Aventis Pharm Prod Inc |
Substituted oxoazaheterocyclyl factor xa inhibitors
|
|
WO2000032590A1
(en)
|
1998-11-25 |
2000-06-08 |
Aventis Pharmaceuticals Products Inc. |
SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
|
|
HUP0203375A3
(en)
|
1999-07-28 |
2005-03-29 |
Aventis Pharm Prod Inc |
Substituted oxoazaheterocyclyl compounds
|
|
JP2001131173A
(ja)
|
1999-08-23 |
2001-05-15 |
Kyorin Pharmaceut Co Ltd |
二環式複素環誘導体
|
|
JP2005231995A
(ja)
|
1999-12-22 |
2005-09-02 |
Meiji Seika Kaisha Ltd |
オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
|
|
US7084126B1
(en)
|
2000-05-01 |
2006-08-01 |
Healthpartners Research Foundation |
Methods and compositions for enhancing cellular function through protection of tissue components
|
|
EP1316203A2
(en)
|
2000-06-30 |
2003-06-04 |
Eli Lilly And Company |
Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
|
|
JP2004532200A
(ja)
|
2001-03-15 |
2004-10-21 |
サエジス ファーマシューティカルズ， インコーポレイテッド |
全身性ストレスの後に認識機能を回復するための方法
|
|
US20040023951A1
(en)
|
2001-06-18 |
2004-02-05 |
Bymaster Franklin Porter |
Combination therapy for treatment of psychoses
|
|
US20030004913A1
(en)
|
2001-07-02 |
2003-01-02 |
Koninklijke Philips Electronics N.V. |
Vision-based method and apparatus for detecting an event requiring assistance or documentation
|
|
EP1448537A4
(en)
|
2001-11-26 |
2005-05-04 |
Cortex Pharma Inc |
CARBONYLBENZOXAZINIC COMPOUNDS ENHANCING SYNAPTIC GLUTAMATERGIC RESPONSES
|
|
US20040044023A1
(en)
|
2002-08-30 |
2004-03-04 |
Marc Cantillon |
Compositions and methods for treating or preventing memory impairment
|
|
US20060233843A1
(en)
|
2003-02-19 |
2006-10-19 |
Conn P J |
Treatment of psychosis with a muscarinic m1 receptor ectopic activator
|
|
EP1613321A2
(en)
|
2003-03-28 |
2006-01-11 |
Acadia Pharmaceuticals Inc. |
Muscarinic m1 receptor agonists for pain management
|
|
US20040266659A1
(en)
|
2003-06-27 |
2004-12-30 |
Stephen LaBerge |
Substances that enhance recall and lucidity during dreaming
|
|
GB0504019D0
(en)
|
2005-02-26 |
2005-04-06 |
Astrazeneca Ab |
Amide derivatives
|
|
EP1885708A2
(en)
|
2005-04-15 |
2008-02-13 |
Board of Trustees of Michigan State University |
Gpcr modulators
|
|
GB0516570D0
(en)
|
2005-08-12 |
2005-09-21 |
Astrazeneca Ab |
Amide derivatives
|
|
US20110319386A1
(en)
|
2005-08-26 |
2011-12-29 |
Braincells Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
US7678363B2
(en)
|
2005-08-26 |
2010-03-16 |
Braincells Inc |
Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
|
|
WO2007044937A2
(en)
|
2005-10-13 |
2007-04-19 |
President And Fellows Of Harvard College |
Compositions and methods to modulate memory
|
|
UA98297C2
(en)
|
2005-12-21 |
2012-05-10 |
Янссен Фармацевтика, Н.В. |
Triazolopyridazines as tyrosine kinase modulators
|
|
GB0607949D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res The Ltd |
Mono and combination therapy
|
|
GB0607946D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res The Ltd |
Mono and combination therapy
|
|
GB0607952D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res Ltd |
Novel treatment
|
|
PE20121506A1
(es)
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
US7834023B2
(en)
|
2006-09-20 |
2010-11-16 |
Portola Pharmaceuticals, Inc. |
Substituted dihydroquinazolines as platelet ADP receptor inhibitors
|
|
AP2502A
(en)
|
2007-01-03 |
2012-10-23 |
Servier Lab |
3-substituted-[1,2,3]-benzotriazinone compound forenhancing glutamatergic synaptic responses
|
|
US8618074B2
(en)
|
2007-03-15 |
2013-12-31 |
Board Of Regents Of The University Of Texas System |
GPCR enhanced neuroprotection to treat brain injury
|
|
CN101821252A
(zh)
|
2007-08-29 |
2010-09-01 |
先灵公司 |
取代的吲哚衍生物及其使用方法
|
|
TW200924751A
(en)
|
2007-08-29 |
2009-06-16 |
Schering Corp |
2,3-substituted indole derivatives and methods of use thereof
|
|
KR20100065167A
(ko)
|
2007-08-29 |
2010-06-15 |
쉐링 코포레이션 |
바이러스 감염 치료용 2,3-치환된 아자인돌 유도체
|
|
CA2700332A1
(en)
|
2007-09-21 |
2009-03-26 |
Acadia Pharmaceuticals, Inc. |
N-substituted piperidine derivatives as serotonin receptor agents
|
|
WO2009039460A2
(en)
|
2007-09-21 |
2009-03-26 |
Acadia Pharmaceuticals, Inc. |
Co-administration of pimavanserin with other agents
|
|
US8765757B2
(en)
|
2007-11-16 |
2014-07-01 |
Merck Sharp & Dohme Corp. |
3-heterocyclic substituted indole derivatives and methods of use thereof
|
|
MX2010005355A
(es)
|
2007-11-16 |
2010-06-02 |
Schering Corp |
Derivados de indol sustituidos con 3-aminosulfonilo y metodos de uso de los mismos.
|
|
US20110024198A1
(en)
|
2008-02-19 |
2011-02-03 |
Baker Hughes Incorporated |
Bearing systems containing diamond enhanced materials and downhole applications for same
|
|
WO2010042603A1
(en)
|
2008-10-08 |
2010-04-15 |
Cingulate Neuro Therapeutics, Llc |
Amyloid and depression
|
|
JP5102397B2
(ja)
|
2008-11-20 |
2012-12-19 |
メルク・シャープ・エンド・ドーム・コーポレイション |
アリールメチルベンゾキナゾリノンｍ１レセプターポジティブアロステリックモジュレーター
|
|
WO2010096338A1
(en)
|
2009-02-23 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
|
|
SG174220A1
(en)
|
2009-03-05 |
2011-10-28 |
Mithridion Inc |
Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
|
|
WO2010123716A1
(en)
|
2009-04-20 |
2010-10-28 |
Merck Sharp & Dohme Corp. |
Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
|
|
ES2353093B1
(es)
|
2009-05-20 |
2012-01-03 |
Consejo Superior De Investigaciones Científicas (Csic) |
Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas.
|
|
CA2804215C
(en)
|
2009-07-22 |
2019-10-01 |
Eric Elenko |
Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
|
|
US10265311B2
(en)
|
2009-07-22 |
2019-04-23 |
PureTech Health LLC |
Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
|
|
NZ598462A
(en)
|
2009-08-31 |
2012-12-21 |
Merck Sharp & Dohme |
Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
|
|
EP2490692B1
(en)
|
2009-10-21 |
2016-11-16 |
Merck Sharp & Dohme Corp. |
Quinolinone-pyrazolone m1 receptor positive allosteric modulators
|
|
EP2512245B1
(en)
|
2009-12-14 |
2014-07-23 |
Merck Sharp & Dohme Corp. |
Pyridoquinazolinone m1 receptor positive allosteric modulators
|
|
EP2515656B1
(en)
|
2009-12-21 |
2014-08-06 |
Merck Sharp & Dohme Corp. |
Aminobenzoquinazolinone m1 receptor positive allosteric modulators
|
|
WO2011159553A1
(en)
|
2010-06-15 |
2011-12-22 |
Merck Sharp & Dohme Corp. |
Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
|
|
WO2012003147A1
(en)
|
2010-07-01 |
2012-01-05 |
Merck Sharp & Dohme Corp. |
Isoindolone m1 receptor positive allosteric modulators
|
|
WO2012047702A1
(en)
|
2010-10-04 |
2012-04-12 |
Merck Sharp & Dohme Corp. |
Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
|
|
US9549928B2
(en)
|
2011-04-29 |
2017-01-24 |
The University Of Toledo |
Muscarinic agonists as enhancers of cognitive flexibility
|
|
EP2709624B1
(en)
*
|
2011-05-17 |
2016-04-27 |
Merck Sharp & Dohme Corp. |
N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
|
|
WO2012170599A1
(en)
|
2011-06-10 |
2012-12-13 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
US9403802B2
(en)
|
2012-03-02 |
2016-08-02 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use therefor
|
|
EA028382B1
(ru)
|
2012-03-23 |
2017-11-30 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Соединения для лечения спинальной мышечной атрофии
|
|
US20130289019A1
(en)
|
2012-04-26 |
2013-10-31 |
Amazing Grace, Inc. |
Methods of treating behaviorial and/or mental disorders
|
|
US9777005B2
(en)
|
2012-11-19 |
2017-10-03 |
Takeda Pharmaceutical Company Limited |
Bicyclic heterocyclic compound containing a substituted pyrrole ring
|
|
JP6075408B2
(ja)
|
2012-11-22 |
2017-02-08 |
株式会社デンソー |
物標検出装置
|
|
CA2886139A1
(en)
|
2012-12-27 |
2014-07-03 |
F. Hoffmann-La Roche Ag |
Comt inhibitors
|
|
JP6402115B2
(ja)
|
2013-02-04 |
2018-10-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
神経学的疾患および状態の処置に有用なスピロ−キナゾリノン誘導体
|
|
KR101819567B1
(ko)
|
2013-05-06 |
2018-02-28 |
가천대학교 산학협력단 |
혈관신생-매개된 질환의 치료용 화합물
|
|
JP6063400B2
(ja)
|
2014-01-08 |
2017-01-18 |
株式会社日立ビルシステム |
エレベータの異常監視装置
|
|
EA030373B1
(ru)
|
2014-04-23 |
2018-07-31 |
Такеда Фармасьютикал Компани Лимитед |
Изоиндолин-1-оновые производные в качестве положительных аллостерических модуляторов холинергического мускаринового m1 рецептора для лечения болезни альцгеймера
|
|
US10208046B2
(en)
|
2014-05-16 |
2019-02-19 |
Takeda Pharmaceutical Company Limited |
Nitrogen-containing heterocyclic compound
|
|
US10214508B2
(en)
|
2014-06-13 |
2019-02-26 |
Takeda Pharmaceutical Company Limited |
Nitrogen-containing heterocyclic compound
|
|
EP3313836B1
(en)
*
|
2015-06-26 |
2020-11-11 |
Takeda Pharmaceutical Company Limited |
2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
|
|
US20180250270A1
(en)
|
2015-09-11 |
2018-09-06 |
Chase Pharmaceuticals Corporation |
Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
|
|
WO2017069173A1
(ja)
|
2015-10-20 |
2017-04-27 |
武田薬品工業株式会社 |
複素環化合物
|
|
JP6860551B2
(ja)
|
2016-03-11 |
2021-04-14 |
武田薬品工業株式会社 |
芳香環化合物
|
|
WO2018122845A1
(en)
|
2016-12-29 |
2018-07-05 |
Rvx Therapeutics Ltd. |
Methods and compositions for potentiating cns drugs and reducing their side effects
|